Esperion Therapeutics, Inc.
ESPR
$2.18
-$0.01-0.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 268.13M | 259.57M | 332.31M | 295.45M | 277.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 268.13M | 259.57M | 332.31M | 295.45M | 277.79M |
| Cost of Revenue | 144.17M | 135.46M | 114.84M | 107.43M | 108.00M |
| Gross Profit | 123.96M | 124.12M | 217.48M | 188.03M | 169.78M |
| SG&A Expenses | 159.41M | 164.08M | 163.07M | 171.57M | 164.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 303.57M | 299.54M | 277.91M | 279.00M | 272.84M |
| Operating Income | -35.45M | -39.96M | 54.40M | 16.46M | 4.95M |
| Income Before Tax | -104.02M | -153.22M | -51.75M | -86.77M | -98.50M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.02 | -153.22 | -51.75 | -86.77 | -98.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.02M | -153.22M | -51.75M | -86.77M | -98.50M |
| EBIT | -35.45M | -39.96M | 54.40M | 16.46M | 4.95M |
| EBITDA | -35.34M | -39.88M | 54.50M | 16.53M | 5.03M |
| EPS Basic | -0.53 | -0.79 | -0.23 | -0.62 | -0.84 |
| Normalized Basic EPS | -0.33 | -0.32 | 0.04 | -0.21 | -0.35 |
| EPS Diluted | -0.53 | -0.80 | -0.25 | -0.65 | -0.86 |
| Normalized Diluted EPS | -0.33 | -0.32 | 0.01 | -0.24 | -0.37 |
| Average Basic Shares Outstanding | 784.17M | 775.42M | 748.55M | 665.39M | 582.33M |
| Average Diluted Shares Outstanding | 784.17M | 775.42M | 768.93M | 685.77M | 602.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |